Desarrollo experimental de controladores Fuzzy para procesos térmicos y neumáticos

In this project, a Fuzzy control system is proposed in an industrial process training module with two independent systems between them, one thermal and the other pneumatic. The control algorithm is developed in Python language v3.6 executed by a Raspberry Pi B+, both controllers depend on the error and change in error that are updated in times of 2 s and 1 s, for temperature and pressure respectively, communication with the plants uses A/D and D/A converters, the thermal Fuzzy was analyzed with three temperature references [50,100 and 150]°C, with a rise time of 191 s, 360 s and 505 s; steady state error of 5.5%, 0.7% y 0.7%, in the pneumatic system the speed of change between references is evaluated from 10 psi to 15 psi varying the activation of the compressor at the beginning of the experiments, the settling times obtained are 111 s and 106 s, with the compressor off the result is 116 s and 88 s, besides a maximum excess of 13% with inherent oscillations to the type system that are in an acceptable range. En este proyecto, se propone un sistema de control Fuzzy en un módulo de entrenamiento de procesos industriales con dos sistemas independientes entre sí, uno térmico y otro neumático, el algoritmo de control se desarrolla en lenguaje Python v3.6 ejecutado por una Raspberry Pi B+, ambos controladores dependen del error y cambio en el error que se actualizan en tiempos de 2 s y 1 s, para temperatura y presión respectivamente, la comunicación con las plantas emplea conversores A/D y D/A, el Fuzzy térmico se analizo con tres referencias de temperatura [50,100 y 150]°C, con un tiempo de subida de 191 s, 360 s y 505 s; error de estado estacionario de 5.5 %, 0.7% y 0.7 %, en el sistema neumático se evalúo la velocidad de cambio entre referencias de 10 psi a 15 psi variando la activación del compresor al inicio de los experimentos, los tiempos de asentamiento que se obtienen son 111 s y 106 s, con el compresor apagado el resultado es de 116 s y 88 s, además de un sobrepaso máximo de 13% con oscilaciones inherentes al tipo sistema que se encuentran en un rango aceptable.&nbsp

Erratum to: Methods for evaluating medical tests and biomarkers

[This corrects the article DOI: 10.1186/s41512-016-0001-y.]

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Evidence synthesis to inform model-based cost-effectiveness evaluations of diagnostic tests: a methodological systematic review of health technology assessments

Background: Evaluations of diagnostic tests are challenging because of the indirect nature of their impact on patient outcomes. Model-based health economic evaluations of tests allow different types of evidence from various sources to be incorporated and enable cost-effectiveness estimates to be made beyond the duration of available study data. To parameterize a health-economic model fully, all the ways a test impacts on patient health must be quantified, including but not limited to diagnostic test accuracy. Methods: We assessed all UK NIHR HTA reports published May 2009-July 2015. Reports were included if they evaluated a diagnostic test, included a model-based health economic evaluation and included a systematic review and meta-analysis of test accuracy. From each eligible report we extracted information on the following topics: 1) what evidence aside from test accuracy was searched for and synthesised, 2) which methods were used to synthesise test accuracy evidence and how did the results inform the economic model, 3) how/whether threshold effects were explored, 4) how the potential dependency between multiple tests in a pathway was accounted for, and 5) for evaluations of tests targeted at the primary care setting, how evidence from differing healthcare settings was incorporated. Results: The bivariate or HSROC model was implemented in 20/22 reports that met all inclusion criteria. Test accuracy data for health economic modelling was obtained from meta-analyses completely in four reports, partially in fourteen reports and not at all in four reports. Only 2/7 reports that used a quantitative test gave clear threshold recommendations. All 22 reports explored the effect of uncertainty in accuracy parameters but most of those that used multiple tests did not allow for dependence between test results. 7/22 tests were potentially suitable for primary care but the majority found limited evidence on test accuracy in primary care settings. Conclusions: The uptake of appropriate meta-analysis methods for synthesising evidence on diagnostic test accuracy in UK NIHR HTAs has improved in recent years. Future research should focus on other evidence requirements for cost-effectiveness assessment, threshold effects for quantitative tests and the impact of multiple diagnostic tests

Erratum to: Methods for evaluating medical tests and biomarkers

[This corrects the article DOI: 10.1186/s41512-016-0001-y.]

Experimental Development of Fuzzy Controllers for Thermal and Pneumatic Processes

In this project, a Fuzzy control system is proposed in an industrial process training module with two independent systems between them, one thermal and the other pneumatic. The control algorithm is developed in Python language v3.6 executed by a Raspberry Pi B+, both controllers depend on the error and change in error that are updated in times of 2 s and 1 s, for temperature and pressure respectively, communication with the plants uses A/D and D/A converters, the thermal Fuzzy was analyzed with three temperature references [50,100 and 150]°C, with a rise time of 191 s, 360 s and 505 s; steady state error of 5.5%, 0.7% y 0.7%, in the pneumatic system the speed of change between references is evaluated from 10 psi to 15 psi varying the activation of the compressor at the beginning of the experiments, the settling times obtained are 111 s and 106 s, with the compressor off the result is 116 s and 88 s, besides a maximum excess of 13% with inherent oscillations to the type system that are in an acceptable range

Experimental Development of Fuzzy Controllers for Thermal and Pneumatic Processes

In this project, a Fuzzy control system is proposed in an industrial process training module with two independent systems between them, one thermal and the other pneumatic. The control algorithm is developed in Python language v3.6 executed by a Raspberry Pi B+, both controllers depend on the error and change in error that are updated in times of 2 s and 1 s, for temperature and pressure respectively, communication with the plants uses A/D and D/A converters, the thermal Fuzzy was analyzed with three temperature references [50,100 and 150]°C, with a rise time of 191 s, 360 s and 505 s; steady state error of 5.5%, 0.7% y 0.7%, in the pneumatic system the speed of change between references is evaluated from 10 psi to 15 psi varying the activation of the compressor at the beginning of the experiments, the settling times obtained are 111 s and 106 s, with the compressor off the result is 116 s and 88 s, besides a maximum excess of 13% with inherent oscillations to the type system that are in an acceptable range. En este proyecto, se propone un sistema de control Fuzzy en un módulo de entrenamiento de procesos industriales con dos sistemas independientes entre sí, uno térmico y otro neumático, el algoritmo de control se desarrolla en lenguaje Python v3.6 ejecutado por una Raspberry Pi B+, ambos controladores dependen del error y cambio en el error que se actualizan en tiempos de 2 s y 1 s, para temperatura y presión respectivamente, la comunicación con las plantas emplea conversores A/D y D/A, el Fuzzy térmico se analizo con tres referencias de temperatura [50,100 y 150]°C, con un tiempo de subida de 191 s, 360 s y 505 s; error de estado estacionario de 5.5 %, 0.7% y 0.7 %, en el sistema neumático se evalúo la velocidad de cambio entre referencias de 10 psi a 15 psi variando la activación del compresor al inicio de los experimentos, los tiempos de asentamiento que se obtienen son 111 s y 106 s, con el compresor apagado el resultado es de 116 s y 88 s, además de un sobrepaso máximo de 13% con oscilaciones inherentes al tipo sistema que se encuentran en un rango aceptable.

Erratum to: Methods for evaluating medical tests and biomarkers

The original MEMTAB Abstracts in Diagnostic and Prognostic Research contains the incorrect year on individual abstracts in the PDF [1].“Diagnostic and Prognostic Research 2016” under the correspondence line should therefore have been written as “Diagnostic and Prognostic Research 2017” as the journal did not launch until 2017